Summary by Futu AI
Genscript Bio, a non-wholly-owned subsidiary of Genscript Biotech, announced its unaudited financial performance for the first six months ending on June 30, 2024 on July 26, 2024.In that period, Legend Biotech is expected to record an adjusted net loss of $94.7 million to $109.7 million. This preliminary performance is estimated based on the available data and will provide a full financial report on August 9, 2024. Legend Biotech is a global biotechnology company dedicated to developing cell therapies, whose shares are listed on the Nasdaq Global Select Market in the United States. The company emphasized that the final performance may differ from the preliminary estimate because the financial settlement process is not yet completed and reminded investors to pay attention to investment risks.